Gilead’s Hepatitis C Drug to Get Priority Review by FDA

Gilead Sciences Inc., the world’s largest maker of HIV medicines, said its experimental hepatitis C pill, sofosbuvir, will receive a priority marketing review by U.S. regulators.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.